multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Prof. Em. Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. Membrane Hsp70 expression is a negative prognostic indicator in a number of cancers. This form of Hsp70 is therefore an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics ('theranostics').

Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of cancer therapeutics. ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill the large proportion of cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to cytolytic T cell immunotherapies. This proprietary autologous natural killer (NK) cell therapy targeting membrane Hsp70 has successfully demonstrated safety and delivered signs of efficacy in completed Phase I and Phase II clinical trials in Germany.

Membrane Hsp70-expressing tumors can also be imaged and targeted using theranostics based on a unique monoclonal antibody which can detect the membrane form of Hsp70 and  a patented peptide which binds to membrane Hsp70.

multimmune's lead diagnostic candidate is the patented and CE-marked Hsp70-exo enzyme immunoassay (ELISA) which detects lipid-associated Hsp70 in the blood, levels of which can be used to detect the presence of tumors expressing membrane Hsp70 and prognosticate disease, as well as monitor therapeutic response and disease recurrence.

multimmune GmbH

Org chart

Teams

Offices